JAMA Oncology
Original Investigation
October 1, 2019
Guillaume Assié, MD, PhD; Anne Jouinot, MD; Martin Fassnacht, MD, PhD; Rossella Libé, MD; Simon Garinet, PharmD; Louis Jacob, BS; Nadim Hamzaoui, MD; Mario Neou, MS; Julien Sakat, MD; Bruno de La Villéon, MD; Karine Perlemoine, BS; Bruno Ragazzon, PhD; Mathilde Sibony, MD; Frédérique Tissier, MD; Sébastien Gaujoux, MD, PhD; Bertrand Dousset, MD, PhD; Silviu Sbiera, MD, PhD; Cristina L. Ronchi, MD, PhD; Matthias Kroiss, MD, PhD; Esther Korpershoek, PhD; Ronald De Krijger, MD, PhD; Jens Waldmann, MD, PhD; Marcus Quinkler, MD, PhD; Magalie Haissaguerre, MD, PhD; Antoine Tabarin, MD, PhD; Olivier Chabre, MD, PhD; Michaela Luconi, MD, PhD; Massimo Mannelli, MD, PhD; Lionel Groussin, MD, PhD; Xavier Bertagna, MD, PhD; Eric Baudin, MD, PhD; Laurence Amar, MD, PhD; Joel Coste, MD, PhD; Felix Beuschlein, MD, PhD; Jérôme Bertherat, MD, PhD
free access
JAMA Oncol. 2019; 5(10):1440-1447. doi: 10.1001/jamaoncol.2019.1558
This biomarker analyss of patients with adrenocortical carcinoma compares the molecular classification for prognostic assessment of adrenocortical carcinoma with other known prognostic factors.